Juvenile Arthritis News

ORLANDO, Fla. — Periodic fever syndromes call for careful documentation, school and work accommodations, and patient education, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Tofacitinib’s benefits in patients with juvenile idiopathic arthritis extend through at least 48 months, with no new safety findings, according to data published in Annals of the Rheumatic Diseases.

Fatigue partially mediates the relationship between pain interference and physical disability in juvenile idiopathic arthritis, according to data published in Arthritis Care & Research.

Juvenile arthritis can impact the physical and emotional wellbeing of children in unique ways, manifesting in loneliness and depression, according to the Arthritis Foundation.

“Your foot is very swollen. Like, there’s definitely something really wrong with your foot.”

Most pediatric patients with Sjögren’s disease displayed an interferon signature in their blood and parotid gland tissue, which could help confirm diagnoses and shorten treatment delays, according to data presented at EULAR 2024 Congress.

Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus erythematosus, according to data presented at EULAR 2024 Congress.

Converting an empty building into an information hub and social media campaigns were among the “innovative” strategies employed by a U.K.-based patient organization to raise awareness of juvenile arthritis, according to EULAR.

Caregivers of pediatric rheumatology patients transitioning to adult care reported a “lack of clear information” on the necessary procedures, according to data presented at the EULAR 2024 Congress.

The FDA has approved the interleukin-6 inhibitor Kevzara for the treatment of polyarticular juvenile idiopathic arthritis, according to a press release from Regeneron Pharmaceuticals and Sanofi.